Capital Health

capital-health.ae

Capital Health, headquartered in Abu Dhabi, is a private integrated healthcare group that operates two healthcare facilities in the UAE: Specialized Rehabilitation Hospital (SRH) - a specialty hospital that provides acute and long-term rehabilitation care, along with inpatient, outpatient and Home Health capabilities; and Health Shield Medical Center - a multi-specialty healthcare facility with outpatient (one-day surgery) capabilities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

FAUNA BIO'S COMPARATIVE GENOMICS APPROACH FINDS NEW COMPOUNDS FOR HEART AND LUNG DISEASES

Fauna | June 15, 2022

news image

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...

Read More

RESEARCH

VIPERGEN COLLABORATES WITH ANAVO THERAPEUTICS TO SUPPORT PHOSPHATASE-TARGETED DISCOVERY PROGRAMS

Vipergen ApS, Anavo Therapeutics | May 18, 2021

news image

Vipergen, a leading supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technologies, has signed a drug discovery service agreement with Anavo Therapeutics. Vipergen will use its patented high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets, according to the terms of the agreement. The agreement's financial terms were not disclosed. "Vipergen'...

Read More

AI

PEPTILOGICS AND CEREBRAS SYSTEMS PARTNER ON AI SOLUTIONS TO ADVANCE THE FUTURE OF PEPTIDE THERAPEUTICS

Cerebras Systems , Peptilogics | August 19, 2021

news image

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras CS-2 system – powered by the world’s fastest AI processor – Peptilogics will be able to push the boundaries ...

Read More

LIFEMINE THERAPEUTICS AND GSK ENTER DRUG DISCOVERY AND DEVELOPMENT ALLIANCE

LifeMine | March 28, 2022

news image

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced a strategic R&D collaboration with GlaxoSmithKline (GSK). The collaboration will provide GSK with access to LifeMine’s genomically enabled drug discovery platform to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas. Under the te...

Read More
news image

MEDICAL

FAUNA BIO'S COMPARATIVE GENOMICS APPROACH FINDS NEW COMPOUNDS FOR HEART AND LUNG DISEASES

Fauna | June 15, 2022

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...

Read More
news image

RESEARCH

VIPERGEN COLLABORATES WITH ANAVO THERAPEUTICS TO SUPPORT PHOSPHATASE-TARGETED DISCOVERY PROGRAMS

Vipergen ApS, Anavo Therapeutics | May 18, 2021

Vipergen, a leading supplier of small-molecule drug discovery services focused on DNA-encoded library (DEL) technologies, has signed a drug discovery service agreement with Anavo Therapeutics. Vipergen will use its patented high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads against selected Anavo discovery targets, according to the terms of the agreement. The agreement's financial terms were not disclosed. "Vipergen'...

Read More
news image

AI

PEPTILOGICS AND CEREBRAS SYSTEMS PARTNER ON AI SOLUTIONS TO ADVANCE THE FUTURE OF PEPTIDE THERAPEUTICS

Cerebras Systems , Peptilogics | August 19, 2021

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI. Leveraging the revolutionary Cerebras CS-2 system – powered by the world’s fastest AI processor – Peptilogics will be able to push the boundaries ...

Read More
news image

LIFEMINE THERAPEUTICS AND GSK ENTER DRUG DISCOVERY AND DEVELOPMENT ALLIANCE

LifeMine | March 28, 2022

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced a strategic R&D collaboration with GlaxoSmithKline (GSK). The collaboration will provide GSK with access to LifeMine’s genomically enabled drug discovery platform to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas. Under the te...

Read More